Defibrotide

Breastfeeding
  • TRADE NAME: Defitelio (Jazz)
  • INDICATIONS: Hepatic veno-occlusive disease in patients with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation
  • CLASS: Oligonucleotide
  • HALF-LIFE: <2 hours

FDA APPROVAL DATE: 03/30/2016

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alteplase, Heparin

PREGNANCY CATEGORY: N/A
No data available

NOTE

Contra-indicated for concomitant administration with systemic anticoagulant or fibrinolytic therapy.

Our database has 31 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
RENAL
HEMATOLOGIC
LOCAL
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric